Terms: = Prostate cancer AND TOP2A, TOP2, TP2A AND Treatment
16 results:
1. BAZ2A-RNA mediated association with top2a and KDM1A represses genes implicated in prostate cancer.
Roganowicz M; Bär D; Bersaglieri C; Aprigliano R; Santoro R
Life Sci Alliance; 2023 Jul; 6(7):. PubMed ID: 37184661
[TBL] [Abstract] [Full Text] [Related]
2. A machine learning framework develops a DNA replication stress model for predicting clinical outcomes and therapeutic vulnerability in primary prostate cancer.
Huang RH; Hong YK; Du H; Ke WQ; Lin BB; Li YL
J Transl Med; 2023 Jan; 21(1):20. PubMed ID: 36635710
[TBL] [Abstract] [Full Text] [Related]
3. Identification of the Key Genes Involved in the Tumorigenesis and Prognosis of prostate cancer.
Wang W; Wu Q; Mohyeddin A; Liu Y; Liu Z; Ge J; Zhang B; Shi G; Wang W; Wu D; Wang F
Comput Math Methods Med; 2022; 2022():5500416. PubMed ID: 36245843
[TBL] [Abstract] [Full Text] [Related]
4. Molecular Profile Changes in Patients with Castrate-Resistant prostate cancer Pre- and Post-Abiraterone/Prednisone treatment.
Sicotte H; Kalari KR; Qin S; Dehm SM; Bhargava V; Gormley M; Tan W; Sinnwell JP; Hillman DW; Li Y; Vedell PT; Carlson RE; Bryce AH; Jimenez RE; Weinshilboum RM; Kohli M; Wang L
Mol Cancer Res; 2022 Dec; 20(12):1739-1750. PubMed ID: 36135372
[TBL] [Abstract] [Full Text] [Related]
5. Targeting DNA topoisomerase IIα (top2a) in the hypoxic tumour microenvironment using unidirectional hypoxia-activated prodrugs (uHAPs).
Smith PJ; McKeown SR; Patterson LH
IUBMB Life; 2023 Jan; 75(1):40-54. PubMed ID: 35499745
[TBL] [Abstract] [Full Text] [Related]
6. Environmental Phenol and Paraben Exposure Risks and Their Potential Influence on the Gene Expression Involved in the Prognosis of prostate cancer.
Alwadi D; Felty Q; Roy D; Yoo C; Deoraj A
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409038
[TBL] [Abstract] [Full Text] [Related]
7. Biomarkers for Predicting Abiraterone treatment Outcome and Selecting Alternative Therapies in Castration-Resistant prostate cancer.
Qin S; Gao H; Kim W; Zhang H; Gu Y; Kalari KR; Sinnwell JP; Scholz JA; Xie F; Yin P; Yu J; Qin B; Zhuang Y; Wei L; Tan W; Bryce AH; Weinshilboum RM; Wang L
Clin Pharmacol Ther; 2022 Jun; 111(6):1296-1306. PubMed ID: 35288936
[TBL] [Abstract] [Full Text] [Related]
8. Prediction of recurrence from metabolites and expression of top2a and EZH2 in prostate cancer patients treated with radiotherapy.
Hansen AF; Høiem TS; Selnaes KM; Bofin AM; Størkersen Ø; Bertilsson H; Wright AJ; Giskeødegård GF; Bathen TF; Rye MB; Tessem MB
NMR Biomed; 2023 May; 36(5):e4694. PubMed ID: 35032074
[TBL] [Abstract] [Full Text] [Related]
9. Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways.
Hongo H; Kosaka T; Suzuki Y; Mikami S; Fukada J; Oya M
Sci Rep; 2021 Nov; 11(1):22284. PubMed ID: 34782700
[TBL] [Abstract] [Full Text] [Related]
10. Ciprofloxacin and Levofloxacin as Potential Drugs in Genitourinary cancer treatment-The Effect of Dose-Response on 2D and 3D Cell Cultures.
Kloskowski T; Szeliski K; Fekner Z; Rasmus M; Dąbrowski P; Wolska A; Siedlecka N; Adamowicz J; Drewa T; Pokrywczyńska M
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769400
[TBL] [Abstract] [Full Text] [Related]
11. Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study.
Cattrini C; Capaia M; Boccardo F; Barboro P
Cancer Treat Res Commun; 2020; 25():100221. PubMed ID: 33091733
[TBL] [Abstract] [Full Text] [Related]
12. Topoisomerase 2 Alpha Cooperates with Androgen Receptor to Contribute to prostate cancer Progression.
Schaefer-Klein JL; Murphy SJ; Johnson SH; Vasmatzis G; Kovtun IV
PLoS One; 2015; 10(11):e0142327. PubMed ID: 26560244
[TBL] [Abstract] [Full Text] [Related]
13. top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
Kirk JS; Schaarschuch K; Dalimov Z; Lasorsa E; Ku S; Ramakrishnan S; Hu Q; Azabdaftari G; Wang J; Pili R; Ellis L
Oncotarget; 2015 Feb; 6(5):3136-46. PubMed ID: 25605014
[TBL] [Abstract] [Full Text] [Related]
14. A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer.
Malhotra S; Lapointe J; Salari K; Higgins JP; Ferrari M; Montgomery K; van de Rijn M; Brooks JD; Pollack JR
PLoS One; 2011; 6(5):e20293. PubMed ID: 21629784
[TBL] [Abstract] [Full Text] [Related]
15. The ability of biomarkers to predict systemic progression in men with high-risk prostate cancer treated surgically is dependent on ERG status.
Karnes RJ; Cheville JC; Ida CM; Sebo TJ; Nair AA; Tang H; Munz JM; Kosari F; Vasmatzis G
Cancer Res; 2010 Nov; 70(22):8994-9002. PubMed ID: 21062978
[TBL] [Abstract] [Full Text] [Related]
16. Identification of prognostic biomarkers for prostate cancer.
Kosari F; Munz JM; Savci-Heijink CD; Spiro C; Klee EW; Kube DM; Tillmans L; Slezak J; Karnes RJ; Cheville JC; Vasmatzis G
Clin Cancer Res; 2008 Mar; 14(6):1734-43. PubMed ID: 18347174
[TBL] [Abstract] [Full Text] [Related]
